Clearmind Medicine, Inc. (CMND)
5.87
-0.13
(-2.17%)
USD |
NASDAQ |
Oct 23, 16:00
5.88
+0.01
(+0.17%)
After-Hours: 20:00
Clearmind Medicine Enterprise Value : -1.539M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | -1.539M |
| October 22, 2026 | -1.260M |
| October 21, 2026 | -1.389M |
| October 20, 2026 | -1.002M |
| October 19, 2026 | -1.260M |
| October 16, 2026 | -0.7019M |
| October 15, 2026 | -0.3589M |
| October 14, 2026 | -0.6402M |
| October 13, 2026 | -0.7665M |
| October 12, 2026 | -0.1015M |
| October 09, 2026 | -0.0157M |
| October 08, 2026 | 0.0272M |
| October 07, 2026 | 0.0272M |
| October 06, 2026 | -1.603M |
| October 05, 2026 | -1.260M |
| October 02, 2026 | -1.861M |
| October 01, 2026 | -1.847M |
| September 30, 2026 | -0.314M |
| September 29, 2026 | -0.2062M |
| September 28, 2026 | -0.6129M |
| September 25, 2026 | -0.3503M |
| September 24, 2026 | -0.2251M |
| September 23, 2026 | 0.4563M |
| September 22, 2026 | -0.7245M |
| September 21, 2026 | -0.5631M |
| Date | Value |
|---|---|
| September 18, 2026 | -0.4121M |
| September 17, 2026 | 0.5936M |
| September 16, 2026 | -0.3006M |
| September 15, 2026 | 0.7017M |
| September 14, 2026 | 2.070M |
| September 11, 2026 | 2.459M |
| September 10, 2026 | 2.715M |
| September 09, 2026 | 4.060M |
| September 08, 2026 | 3.545M |
| September 04, 2026 | 5.776M |
| September 03, 2026 | 15.04M |
| September 02, 2026 | 17.62M |
| September 01, 2026 | 17.27M |
| August 31, 2026 | 19.16M |
| August 28, 2026 | 16.07M |
| August 27, 2026 | 16.93M |
| August 26, 2026 | 15.39M |
| August 25, 2026 | 15.22M |
| August 24, 2026 | 14.70M |
| August 21, 2026 | 15.73M |
| August 20, 2026 | 15.56M |
| August 19, 2026 | 18.65M |
| August 18, 2026 | 19.51M |
| August 17, 2026 | 18.30M |
| August 14, 2026 | 17.79M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| InMed Pharmaceuticals, Inc. | 5.455M |
| NervGen Pharma Corp. | 91.00M |
| Milestone Pharmaceuticals, Inc. | 51.92M |
| Appili Therapeutics, Inc. | 10.20M |
| Lexaria Bioscience Corp. | 1.165M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.9073M |
| Total Expenses (Quarterly) | 0.9073M |
| EPS Diluted (Quarterly) | -0.5734 |
| Earnings Yield | -1.50K% |
| Normalized Earnings Yield | -2072.30 |